ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Elevai Labs Inc

Elevai Labs Inc (ELAB)

0.0937
-0.0037
(-3.80%)
Closed 12 October 7:00AM
0.0919
-0.0018
(-1.92%)
After Hours: 10:59AM

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Key stats and details

Current Price
0.0919
Bid
0.0919
Offer
0.095
Volume
5,881,992
0.093 Day's Range 0.100977
0.0781 52 Week Range 4.2442
Market Cap
Previous Close
0.0974
Open
0.1009
Last Trade
1
@
0.0995
Last Trade Time
Financial Volume
US$ 560,490
VWAP
0.095289
Average Volume (3m)
15,331,791
Shares Outstanding
20,192,114
Dividend Yield
-
PE Ratio
-0.42
Earnings Per Share (EPS)
-0.21
Revenue
1.71M
Net Profit
-4.3M

About Elevai Labs Inc

Elevai Labs, Inc., a skincare development company, designs, manufactures, and markets skincare products. Its products include Empower and Enfinity post-skincare procedure care serums for the face, neck, and upper chest regions. The company was formerly known as Reactive Medical Labs Inc. and changed... Elevai Labs, Inc., a skincare development company, designs, manufactures, and markets skincare products. Its products include Empower and Enfinity post-skincare procedure care serums for the face, neck, and upper chest regions. The company was formerly known as Reactive Medical Labs Inc. and changed its name to Elevai Labs, Inc. in December 2021. Elevai Labs, Inc. was incorporated in 2020 and is based in Newport Beach, California. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
Headquarters
Wilmington, Delaware, USA
Founded
-
Elevai Labs Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker ELAB. The last closing price for Elevai Labs was US$0.10. Over the last year, Elevai Labs shares have traded in a share price range of US$ 0.0781 to US$ 4.2442.

Elevai Labs currently has 20,192,114 shares in issue. The market capitalisation of Elevai Labs is US$1.97 million. Elevai Labs has a price to earnings ratio (PE ratio) of -0.42.

ELAB Latest News

Elevai Labs Inc. Commences Offer to Exchange Up to 15,000,000 shares of Common Stock For Shares of Non Tradable. Locked Up Series B Preferred Stock

NEWPORT BEACH, Calif., Oct. 04, 2024 (GLOBE NEWSWIRE) -- Elevai Labs, Inc. (NASDAQ: ELAB) ("Elevai" or the "Company"), a leader in medical aesthetics, today announced the commencement of an...

REPEAT: Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Expands Patent Portfolio with Two New Filings for EL-22 in Muscle Loss Treatment for Obese Patients, Including GLP-1 Receptor Agonist Combinations

Filed two patent applications for lead candidate EL-22, covering muscle loss in obese patients as a monotherapy and in combination with GLP-1 receptor agonistsElevai Biosciences patent portfolio...

Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Expands Patent Portfolio with Two New Filings for EL-22 in Muscle Loss Treatment for Obese Patients, Including GLP-1 Receptor Agonist Combinations

Filed two patent applications for lead candidate EL-22, covering muscle loss in obese patients as a monotherapy and in combination with GLP-1 receptor agonistsElevai Biosciences patent portfolio...

Univest Securities, LLC Announces Closing of $8.0 Million Registered Follow-on Offering for its Client Elevai Labs Inc. (NASDAQ: ELAB)

New York, Sept. 24, 2024 (GLOBE NEWSWIRE) -- Univest Securities, LLC (“Univest”), a member of FINRA and SIPC, and a full-service investment bank and securities broker-dealer firm based in New...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.0138-13.05581835380.10570.11380.0919183584330.10433099CS
4-0.2161-70.16233766230.3080.3750.0781384904900.12181041CS
12-0.4126-81.78394449950.50450.5260.0781153317910.15066705CS
26-0.5433-85.5321158690.63520.760.078172610970.1563143CS
52-3.9081-97.702544.24420.078145730200.26024976CS
156-3.9081-97.702544.24420.078145730200.26024976CS
260-3.9081-97.702544.24420.078145730200.26024976CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
CAMPCAMP4 Therapeutics Corporation
 10.75
(2,587.50%)
378.47k
TWGTop Wealth Group Holding Ltd
US$ 7.14
(233.64%)
154.21M
NIVFNewGenIvf Group Ltd
US$ 0.98
(63.42%)
58.51M
ATIFATIF Holdings Ltd
US$ 1.235
(58.33%)
3.85M
VERBVerb Technology Company Inc
US$ 7.91
(51.82%)
15.55M
BYUBAIYU Holdings Inc
US$ 0.299
(-35.28%)
11.1M
TURBTurbo Energy SA
US$ 2.1511
(-29.01%)
3.2M
SMSTDefiance Daily Target 1.5X Short MSTR ETF
US$ 7.898
(-23.62%)
993.32k
VEEAVeea Inc
US$ 3.27
(-23.24%)
284.95k
INHDInno Holdings Inc
US$ 3.74
(-22.41%)
257.75k
JTAIJet AI Inc
US$ 0.1009
(23.50%)
340.06M
CDTConduit Pharmaceuticals Inc
US$ 0.116
(13.28%)
270.96M
NVDANVIDIA Corporation
US$ 134.80
(-0.01%)
170.26M
LUXHLuxUrban Hotels Inc
US$ 0.0532
(5.35%)
165.94M
TWGTop Wealth Group Holding Ltd
US$ 7.14
(233.64%)
154.21M

ELAB Discussion

View Posts
glenn1919 glenn1919 1 week ago
ELAB.............................https://stockcharts.com/h-sc/ui?s=ELAB&p=W&b=5&g=0&id=p86431144783
👍️0
tw0122 tw0122 1 week ago
.14 now see you at .23 resistance for the dump
👍️0
tw0122 tw0122 1 week ago
EL-22 alongside GLP-1 receptor agonists, marking a significant advancement in obesity treatment.
The newly filed patent applications support the development of EL-22, an engineered probiotic expressing myostatin, designed to revolutionize obesity care by preserving muscle mass while reducing fat mass. EL-22 has successfully completed a Phase 1 clinical trial in South Korea, demonstrating safety and tolerability in healthy volunteers. Elevai now plans to assess the efficacy of EL-22 in combination with leading weight-loss therapies to address muscle wasting—a common side effect of GLP-1 medications—while promoting fat loss.

“While GLP-1 medications such as Ozempic®, Wegovy®, and Mounjaro® dominate the obesity market, a critical gap remains in preserving lean muscle mass during weight loss,” said Deniel Mero, Co-Founder of Elevai Biosciences. “Muscle mass is vital for metabolism, strength, and overall mobility, and our patented EL-22 technology aims to address this unmet need with a first-in-class approach leveraging myostatin inhibition and oral delivery.”

The first patent application, titled “Fusion Protein of MYO-2 for Use in Treating Muscle Loss in Obese Patients” (Patent Application Serial No. 18/895,501), focuses on EL-22 as a monotherapy for treating muscle loss in obese patients. The second patent application, “Combination Therapy of a Fusion Protein of MYO-2 with a GLP-1 Receptor Agonist for Treating Muscle Loss in Obese Patients” (Patent Application Serial No. 18/895,519), covers the use of EL-22 in combination with GLP-1 receptor agonists, enhancing the benefits of current weight-loss drugs by preserving muscle mass.

These patent applications strengthen Elevai's intellectual property portfolio as the Company advances its mission to transform the standard of care for obesity treatment, with the potential to offer a differentiated therapy that preserves muscle loss, a critical component for patient health and quality of life. Elevai Biosciences’ patent portfolio now includes 4 patent applications and 5 issued patents that provide adequate protection in focus markets, including the USA, Japan, China and Korea.

Licensed Product / Nation Patent Application Serial No. Title:
EL-32 USA 18/627,462 Pharmaceutical composition for alleviation, treatment, and prevention of sarcopenia containing microorganism transformed with cell surface display vector operably linked with gene encoding myostatin and activin A proteins as active ingredient
EL-32 Korea 10-2022-0136606 A pharmaceutical composition for alleviation, treatment and prevention of sarcopenia containing a microorganism transformed with a vector expressing myostatin and activin A on the cell surface as an active ingredient
EL-22 USA 18/895,501 Fusion Protein of Myo-2 for Use in Treating Muscle Loss in Obese Patients
EL-22 USA 18/895,519 Combination Therapy of a Fusion Protein of Myo-2 with a GLP-1 Receptor Agonist for Use in Treating Muscle Loss in Obese Patients

Patent No. Registration No. Title:
EL-22 Korea 10-0857861-0000 Surface Expression Vector for Fusion Protein of Myo-2 Peptide Multimer and Myostatin, and Microorganism Transformed by Thereof
EL-22 Korea 10-0872042-0000 Cell Surface Expression Vector of Myostatin and Microorganisms Transformed Thereby
EL-22 USA 8470551 Surface Expression Vector for Fusion Protein of Myo-2 Peptide Multimer and Myostatin, and Microorganism Transformed by Thereof
EL-22 Japan 5634867 Surface Expression Vector for Fusion Protein of Myo-2 Peptide Multimer and Myostatin, and Microorganism Transformed by Thereof
EL-22 China ZL200780101116.2 Surface Expression Vector for Fusion Protein of Myo-2 Peptide Multimer and Myostatin, and Microorganism Transformed by Thereof

👍️0
tw0122 tw0122 1 week ago
Almost hit .15 + 60%
👍️0
Arnold25764 Arnold25764 2 weeks ago
Reverse split in the foreseeable future?

$elab PRE 14c dropped an hour ago https://t.co/rPqjtUmyrE— Joshua Smith (@hokieman04) September 28, 2024
👍️0
glenn1919 glenn1919 2 weeks ago
elab........................
https://stockcharts.com/h-sc/ui?s=elab&p=W&b=5&g=0&id=p86431144783
















👍️0
glenn1919 glenn1919 1 month ago
ELAB...................................https://stockcharts.com/h-sc/ui?s=ELAB&p=W&b=5&g=0&id=p86431144783
👍️0
Awl416 Awl416 1 month ago
Elevai Labs Inc. Subsidiary, Elevai Skincare Inc., Announces Encouraging Data Results Indicating Potential for Hair Restoration Using Proprietary Exosome Technology
👍️0
georgie18 georgie18 1 month ago
ELAB...34...Moving on Patent News...🥳

georgie18

Member Level
Re: georgie18 post# 655074

Monday, August 26, 2024 10:11:31 AM

Post#
655191
of 655453
ELAB...33s clearing here on News...🥳

georgie18

Member Level
Re: georgie18 post# 24

Friday, August 23, 2024 3:52:32 PM

Post#
25
of 28
ELAB...317...coming back here...🥳Alerted at 324...added the 25 range dip...
👍️0
georgie18 georgie18 2 months ago
ELAB...33s clearing here on News...🥳

georgie18

Member Level
Re: georgie18 post# 24

Friday, August 23, 2024 3:52:32 PM

Post#
25
of 28
ELAB...317...coming back here...🥳Alerted at 324...added the 25 range dip...
👍️0
tw0122 tw0122 2 months ago
Catch some .40s then dump again?
👍️0
TheFinalCD TheFinalCD 2 months ago
https://finviz.com/quote.ashx?t=ELAB&ty=c&ta=1&p=d
👍️0
glenn1919 glenn1919 2 months ago
ELAB...................................................https://stockcharts.com/h-sc/ui?s=ELAB&p=W&b=5&g=0&id=p86431144783
👍️0
georgie18 georgie18 2 months ago
ELAB...317...coming back here...🥳Alerted at 324...added the 25 range dip...
👍️0
georgie18 georgie18 2 months ago
ELAB...324... https://schrts.co/khJaWBxK ...Oversold Chart...🥳
👍️0
tw0122 tw0122 2 months ago
Skinning some shorts however won’t last long
👍️0
FALCON1 FALCON1 3 months ago
https://www.zacks.com/stock/news/2300964/the-zacks-analyst-blog-highlights-danaher-morgan-stanley-pfizer-elite-pharmaceuticals-and-oil-dri
https://www.zacks.com/stock/news/2300922/zacks-initiates-coverage-of-elite-pharmaceuticals-with-outperform-recommendation
👍️0
Awl416 Awl416 5 months ago
Elevai Labs Expands with Launch of Elevai Biosciences and Elevai Skincare Subsidiaries, Advancing the Future of Aesthetic Medicines and Exosome Skincare
👍️0
jelaco jelaco 8 months ago
This stock just can't stay up....someone give this pos some Viagra!
👍️0
IoT II IoT II 8 months ago
https://stocktwits.com/3227blake/message/562545429
👍️0
Muhbruh Muhbruh 8 months ago
$ELAB bottom chart 1.8M float no dilution and 6.6 months of cash with 22.07% 13D out today, only 20k short shares left pic.twitter.com/EFsfxgkXqv— STOCKS Gambino (@StocksGambino) February 21, 2024
👍️0
Invest-in-America Invest-in-America 8 months ago
ELAB: Had skin care Patent, 1-wk. ago; maybe now an outright cure for all CANCERS??? (Joking)
👍️0
IoT II IoT II 8 months ago
Goodmorning
👍️0
TheFinalCD TheFinalCD 8 months ago
and then randomly 4am .70-1.65 no news, just some more games

if it breaks 1.65 it could go

otherwise 1 & done pos pump 2.0
👍️0
tw0122 tw0122 8 months ago
ELAB $1.64 just a quick premarket flip they can do all the dilution they want after 7am..lol
👍️0
TheFinalCD TheFinalCD 8 months ago
NO THX https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173636262

EVEN THOUGH i MADE A SMALL TRADE AND SOLD 1.49

ELAB IS STILL A POS IMO
👍️0
tw0122 tw0122 8 months ago
Almost hit 1.30 zones 1.39- 1.60 further up
👍️0
continuity continuity 9 months ago
Dilution? Total mess.
👍️0
continuity continuity 9 months ago
Dilution? Total mess.
👍️0
TheFinalCD TheFinalCD 9 months ago
$ELAB MORE NEWS Reports Strong Preliminary Unaudited Financial Performance for Fiscal Year 2023, Highlighting Significant Revenue Growth and Expanding Global Reach

https://newsfilter.io/articles/elevai-labs-inc-reports-strong-preliminary-unaudited-financial-performance-for-fiscal-year-2023-high-6ea3644ed452e4ef1c28f33c0f9f63c8
👍️0
airman1 airman1 9 months ago
Yes, very strange
Morning news Today the/ Shorts piled in:((

ELEVAI Labs, Inc. Acquires Worldwide License Agreement for Proprietary Stem Cell Manufacturing Technology

ELEVAI Labs to commercialize use of proprietary technology designed to produce high-quality, cGMP grade mesenchymal stromal cells at lower-cost

NEWPORT BEACH, Calif., Jan. 16, 2024 -- InvestorsHub NewsWire -- Elevai Labs, Inc. (Nasdaq: ELAB) a medical aesthetic company specializing in physician-dispensed skincare is pleased to announce it has signed an exclusive, worldwide manufacturing and processing technology licensing agreement with INmune Bio, Inc., [Nasdaq: INMB]. The licensing agreement grants Elevai a license to use INmune Bio's proprietary "EMx" technology, developed by INmune Bio, Inc., CMO, Mark Lowdell, PhD, that enables Elevai to manufacture current Good Manufacturing Practice ("cGMP") grade, human umbilical cord-derived mesenchymal stromal cells (hucMSCs) at a lower cost to Elevai than purchasing hucMSCs outright. Manufactured hucMSCs can be incorporated into certain licensed topical cosmetic products sold in the medical aesthetics skincare market.

Elevai believes incorporating the "EMx" technology into its operations is a step towards the company's goal of achieving vertical manufacturing integration, while also expanding long-term production capabilities and lowering overall costs. Ultimately, Elevai believes controlling its processes through its product pipeline with what it believes to be efficient technologies like "EMx" will allow greater stem cell consistency, purity, and propel Elevai's branded cosmetic products further to maintain the company's position as an industry innovator in the medical aesthetics skincare marke
👍️0
TheFinalCD TheFinalCD 9 months ago
SEC gives no shits

this is exactly why we 100% need Crypto, every share will be tracked every step of the way long or short

now its all a mystery, with offshore BS

cryptonize the stock market to STOP this naked shorting BS

a long time ago one senator wanted to add a serial # like a vin# to every share so companies, and shareholders could account for every share

well crypto enables exactly that, and is fully transparent on the blockchain

#THINKABOUTIT
👍️ 1
airman1 airman1 9 months ago
Classic chat pump & dump naked short
To 1.00;((
👍️0
continuity continuity 9 months ago
definitely not a good way to start a business.
👍️0
TheFinalCD TheFinalCD 9 months ago
LOOKS LIKE NEWS PUMP TO DUMP SHARES IMO

https://elevaiskincare.com/
FLUFFY PUFFY SKIN ..NEWS

OVER EXTENDED POP

GAP & TRAP

BUT -11.11% IS DOWN RIGHT DISGUSTING AFTER BEING UP UP OVER 100% 4.38 HIGH

$ELAB
👍️0
continuity continuity 9 months ago
this is looking very interesting. The rise is due to the acquisition. Why the fall?
👍️0
IoT II IoT II 9 months ago
Hello world:)
👍️0
Monksdream Monksdream 9 months ago
Recent ipo
👍️0

Your Recent History

Delayed Upgrade Clock